Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 7/20 | 0.36 |
| ▸ | SCN4A | P35499 | 7/20 | 0.32 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.32 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.32 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17846199 | 1.00 | TACR1 (0.36) | TACR1SCN4ACACNA1FCACNA1DCACNA1S | |
| SCHEMBL19348978 | 0.85 | CACNA1F (0.34) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL17846210 | 0.80 | S1PR3 (0.34) | — | |
| SCHEMBL17846211 | 0.80 | S1PR3 (0.34) | — | |
| SCHEMBL17846044 | 0.78 | TACR1 (0.36) | TACR1SCN4ACACNA1FCACNA1DCACNA1S | |
| SCHEMBL21219026 | 0.78 | TACR1 (0.36) | TACR1SCN4ACACNA1FCACNA1DCACNA1S | |
| SCHEMBL17846212 | 0.73 | MAPK1 (0.31) | — | |
| SCHEMBL17846183 | 0.71 | MAPK1 (0.42) | — | |
| SCHEMBL17846171 | 0.70 | MAPK1 (0.39) | — | |
| SCHEMBL17846173 | 0.70 | MAPK1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233859-B1 | BRIDGED PYRAZOLOPYRIDINE DERIVATIVES AS ERK INHIBITORS USEFUL FOR THE TREATEMENT OF CANCER | MERCK SHARP & DOHME (US) | 2019-08-07 | — | — | EP | disclosed |
| US-9988397-B2 | ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-06-05 | — | — | US | disclosed |
| EP-3233859-A1 | ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20170267695-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-21 | — | — | US | disclosed |
| WO-2016100051-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267695-A1 | ERK INHIBITORS | MAPK1, MAP3K1, MAPK4 | TACR1 1773/4885SCN4A 3866/4885CACNA1F 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.